BLRX: biolinerx.com Amount of Cash per Share

Corporate emblem and logo of BioLineRx Ltd. (BLRX)

BioLineRx Ltd. (BLRX) revenues are based on the sales of Aphexda and promising developments in pancreatic therapy. Cash per share illustrates financial stability, where the 2.62 level indicates the state of the liquidity parameter. Capital is replenished through insurance company payments in hematology centers, and operating activities strictly comply with environmental standards for chemical waste disposal.

BLRX: BioLineRx Ltd Cash per Share 07/04/2022 - 11/20/2026

Analytical breakdowns for BioLineRx Ltd.

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:BLRX, BioLineRx Corporation
Original product of biolinerx.com

BioLineRx Ltd. possesses strong management that successfully commercializes innovative drugs through strategic partnerships. This metric determines the volume of liquid assets per common share. By analyzing actual cash per share, an investor assesses the company's real cash reserves. A high indicator confirms financial stability, although it may limit the growth rate of quotes. This is a key express-screening tool for identifying overheated stocks.